Loading articles...
Oral Orforglipron Sustains Weight Loss After Injectable GLP-1 Therapy
The ATTAIN-MAINTAIN trial shows oral orforglipron preserves most injectable-achieved weight loss at 52 weeks, offering a scalable transition option.
What Still Eludes Us in MASH Research?
MASH (metabolic dysfunction-associated steatohepatitis) is a complex disease, and while we've made strides, key mechanistic details remain elusive. This demands a sharper focus on translational studies that can directly inform clinical practice.
Unraveling MASH: Implications for Clinical Practice
A new review in Nature Reviews Gastroenterology & Hepatology clarifies the complex interplay of metabolism, inflammation, and fibrosis in metabolic dysfunction-associated steatohepatitis (MASH). This understanding translates to practical guidance for risk s...
SGLT2 Inhibitors: Promise and Peril in Prader-Willi Syndrome?
SGLT2 inhibitors show potential for managing glycemic control in Prader-Willi Syndrome, but clinicians must be vigilant about the risk of renal complications. This necessitates careful patient selection and close monitoring of kidney function throughout tre...
Metformin, Liraglutide, and Gut Microbiome Shifts in Youth-Onset T2D
Youth-onset type 2 diabetes (T2D) poses unique challenges, and this study sheds light on how common treatments like metformin and liraglutide impact the gut microbiome. Understanding these shifts may allow for more targeted therapies and improved outcomes i...
SGLT2 Inhibitors in Prader-Willi Syndrome: Weighing Renal Risks and Glycemic Control
Patients with Prader-Willi Syndrome (PWS) face unique metabolic challenges; SGLT2 inhibitors may offer some benefit, but careful monitoring is essential. This analysis highlights the need for rigorous trials to define the risk-benefit profile of SGLT2 inhib...
SGLT2 Inhibitors in Prader-Willi Syndrome: Weighing Renal Risks
Patients with Prader-Willi Syndrome (PWS) present unique challenges when considering SGLT2 inhibitors due to their metabolic and behavioral complexities. Vigilant monitoring for euglycemic DKA and proactive management of dehydration risks are paramount when...